RAPP Stock Analysis: Buy, Sell, or Hold?
RAPP - Rapport Therapeutics, Inc. Common Stock
$40.79
-0.19 (-0.46%)
▼
5d:
-3.17%
30d:
+4.67%
90d:
+20.36%
BUY
MODERATE Confidence
Analysis Updated: Jul 31, 2026 12:00 AM ET
Earnings: Aug 06, 2026
1d
Get Alerted When RAPP Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: RAPP shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: RAPP shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: RAPP is currently trading at $40.79, which is considered fair relative to its 30-day fair value range of $39.85 to $42.08.
Technical Outlook: Technically, RAPP is in a strong uptrend. The price is currently testing key support at $39.75. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $58.59 (+43.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, RAPP is in a strong uptrend. The price is currently testing key support at $39.75. A bounce from this level would confirm strength, while a break below could signal further downside.
Market Sentiment: The stock shows a mixed technical setup (55/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $58.59 (+43.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$39.85 -
$42.08
Company Quality Score
58/100
(HOLD)
Options IV Signal
39th percentile
(NORMAL)
Volume Confirmation
HIGH
Confidence Score
73.8%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Options fairly priced (IV 39th percentile)
- NEUTRAL: Mixed technical signals (55/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 43.6% below Wall St target ($58.59)
Trading Range Analysis
30-Day Trading Range
$39.85 -
$42.08
Current vs Trading Range
FAIR
Expected Move (7 Days)
±$4.70
(11.5%)
Support & Resistance Levels
Support Level
$39.75
Resistance Level
$44.28
Current Trend
Strong Uptrend
Technical data as of
Aug 3, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-9.56
Wall Street Target
$58.59
(+43.6%)
Share & Embed Analysis
Last updated: August 04, 2026 12:28 AM ET
Data refreshes hourly during market hours. Next update: 1:28 AM
Data refreshes hourly during market hours. Next update: 1:28 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RAPP showing a specific setup today?
Insider Activity (6 Months)
0
Buys
10
Sells
Net
INSIDERS SELLING
Recent Transactions
Rock Ventures V L.P. Thi…
SELL
426005 shares
2026-04-17
Krishnaswamy Yeleswaram
SELL
20225 shares
2026-04-17
Krishnaswamy Yeleswaram
SELL
10200 shares
2026-04-14
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
CRSP
Crispr Therapeutics AG |
BUY
28 analysts |
$87 | 53 HOLD |
|
INSM
Insmed Inc |
STRONG BUY
21 analysts |
$196 | 47 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$557 | 49 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$108 | 60 HOLD |
|
CRNX
Crinetics Pharmaceutical… |
STRONG BUY
17 analysts |
$86 | 47 HOLD |